30 results on '"Jacqueline Tsai"'
Search Results
2. Internal hernia associated with perforated Meckel's diverticulum
- Author
-
Vanessa W. Hui, Jacqueline Tsai, Nirmal Gokarn, and Mindy B. Statter
- Subjects
Meckel's diverticulum ,Obstruction ,Internal hernia ,Pediatrics ,RJ1-570 ,Surgery ,RD1-811 - Abstract
Internal hernia resulting from a perforated Meckel's diverticulum (MD) is an extremely rare complication of MD. A child presenting with signs of obstruction and concomitant sepsis is typically presumed to have perforated acute appendicitis, until proven otherwise intra-operatively. The following case illustrates the importance of recognizing the need for emergent surgery when confronted with an acute abdomen of uncertain etiology and maintaining a broad differential whilst doing so.
- Published
- 2016
- Full Text
- View/download PDF
3. Interactive Shape Sonification for Breast Cancer Localization.
- Author
-
Laura Schütz, Trishia El Chemaly, Emmanuelle Weber, Anh Thien Doan, Jacqueline Tsai, Bruce L. Daniel, Christoph Leuze, and Nassir Navab
- Published
- 2023
- Full Text
- View/download PDF
4. Nipple‐areola‐complex preservation and obesity—Successful in stages
- Author
-
Lauren Daly, Jacqueline Tsai, Kim Stone, Irene Wapnir, Mardi Karin, Derrick Wan, and Arash Momeni
- Subjects
Surgery - Published
- 2023
5. Abstract OT1-09-01: A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS)
- Author
-
Irene Wapnir, Carol Marquez, Kimberly Stone, Kimberly Allison, Wendy DeMartini, Catherine Salem, Jacqueline Tsai, Robert West, Alex McMillan, Melinda Telli, and Kathleen Horst
- Subjects
Cancer Research ,Oncology ,skin and connective tissue diseases - Abstract
Lumpectomy and breast radiotherapy (RT) achieve good longterm control of disease in patients diagnosed with ductal carcinoma in situ (DCIS). In the combined analysis of NSABP B-17/B-24 DCIS trials, these treatments were shown to reduce invasive ipsilateral breast tumor recurrences by 52% compared to lumpectomy alone. RT has been consistently used as an adjuvant to surgery and therefore, little is known of its activity on intact/untreated DCIS. Elucidating the effectiveness of radiation therapy may help optimize the treatment of DCIS and avoid over-treatment.Trial Design The objective of the ongoing phase 2 pilot trial is to evaluate the ablative and treatment effects of neoadjuvant RT (neoRT) on DCIS. Patients diagnosed with DCIS on core needle biopsy are randomized to upfront lumpectomy (Arm 1) followed by partial breast irradiation (PBI) or neoRT PBI followed by delayed surgical excision (Arm 2). Arm 1 serves as a reference group for pathological-radiological correlations as well as to ascertain the rate of upstaging to invasive cancer. The neoRT regimen consists of 6 Gy daily x 5 (consecutive or non-consecutive days) to the intact tumor with a 0.5 cm margin. Surgical excision is delayed 12-16 weeks, allowing for the ablative effects of neoRT to occur. Specific Aims •To determine if neoRT can completely ablate 30% of DCIS cases•To determine if DCIS subtypes exhibit differential sensitivity to neoRT•To evaluate microscopic treatment effects; wound complication rates; post-RT breast imaging changes; and invasive carcinoma rate.Eligibility Women 18 years of age or older diagnosed with DCIS by core needle biopsy and intending to receive breast conserving surgery are eligible. Tumors must be ≤4 cm, discovered as mammographic microcalcifications and/or MRI non-mass enhancement measuring with evidence of residual imaging abnormality after diagnostic needle biopsy. Statistics A total of 50 patients will be recruited. Upstaging to invasive cancer is anticipated to be approximately 10%. With 25 subjects in each arm, we will have 80% power to detect a 30% or higher improvement in the DCIS complete response rate following neoadjuvant PBI. Accrual 10 (open 2019) Contact wapnir@stanford.edu. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478-488. doi:10.1093/jnci/djr027.McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709-715. doi:10.1200/JCO.2014.57.9029. Citation Format: Irene Wapnir, Carol Marquez, Kimberly Stone, Kimberly Allison, Wendy DeMartini, Catherine Salem, Jacqueline Tsai, Robert West, Alex McMillan, Melinda Telli, Kathleen Horst. A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr OT1-09-01.
- Published
- 2022
6. Influence of Imaging Features and Technique on US-guided Tattoo Ink Marking of Axillary Lymph Nodes Removed at Sentinel Lymph Node Biopsy in Women With Breast Cancer
- Author
-
Debra M. Ikeda, Irene Wapnir, Wendy B. DeMartini, Marlen Pajcini, Joanne Edquilang, and Jacqueline Tsai
- Subjects
medicine.medical_specialty ,Radiological and Ultrasound Technology ,Axillary lymph nodes ,medicine.diagnostic_test ,business.industry ,Sentinel lymph node ,Tattoo ink ,medicine.disease ,Axilla ,medicine.anatomical_structure ,Breast cancer ,Biopsy ,medicine ,Medical imaging ,Radiology, Nuclear Medicine and imaging ,Radiology ,business - Abstract
Objective To describe tattoo ink marking of axillary lymph nodes (TIMAN) and the elements leading to successful removal at sentinel lymph node biopsy (SLNB). Methods An IRB-approved retrospective image review was conducted of breast cancer patients who underwent SLNB after TIMAN from February 2013 to August 2017, noting patient and tattooed lymph node (TLN) features, initial biopsy type, time to surgery, if the TLN was identified at surgery, and correlation with the SLN. Cases were divided into two groups: the presurgical group, which had primary surgery, and the pre-neoadjuvant chemotherapy (NACT) group, which underwent surgery after completing NACT. Results Of 30 patients who underwent 32 TIMAN procedures, 10 (33.3%) were presurgical and 20 (66.7%) were pre-NACT. The average lymph node (LN) depth from the skin was 1.6 cm, with an average of 0.3 mL of tattoo ink injected. Of 32 procedures, 29 (90.6%) had US images demonstrating the injection. Of these, 10 (34.5%) were injected in the LN cortex surface and 19 (65.5%) in the middle cortex. Seven (24.1%) were injected in the LN lateral aspect, 12 (41.4%) in the mid aspect, and 10 (34.5%) in the medial aspect. Of 32 LNs, 28 (87.5%) were tattooed immediately after initial biopsy and 4 (12.5%) at a later date. At SLNB, all 32 (100%) TLNs were identified, all correlated with the SLN, and 10 (31.3%) were positive for cancer. Conclusion Using an average of 0.3 mL of tattoo ink, all TLNs were successfully identified for removal at surgery, despite variability in LN and injection factors.
- Published
- 2021
7. Abstract OT3-09-04: A randomized phase II study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS)
- Author
-
Melinda L. Telli, Rachel L. Yang, Carol Marquez, Jacqueline Tsai, Kimberly H. Allison, Robert B. West, Alex McMillan, Kimberly Stone, Wendy B. DeMartini, Frederick M. Dirbas, Kathleen C. Horst, Debra M. Ikeda, Sunita Pal, and Irene Wapnir
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Lumpectomy ,Cancer ,Ductal carcinoma ,medicine.disease ,Radiation therapy ,Breast cancer ,Oncology ,Biopsy ,medicine ,Breast-conserving surgery ,Neoplastic transformation ,Radiology ,business - Abstract
A randomized phase II study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS) Breast radiotherapy (RT) for DCIS has been studied only in the adjuvant setting, following lumpectomy surgery. Adjuvant RT reduced invasive recurrences by 52% in the combined analysis of the two largest DCIS trials NSABP B-17/B-24, and reduced recurrences even for low or intermediate grade DCIS in the RTOG 9804 trial (recurrence 0.9% with RT versus 6.7% without RT). The mechanism of action is hypothesized to be elimination of occult disease and/or inhibition of neoplastic transformation in normal breast tissue. Trial Design To understand the ablative effects of RT on pure DCIS, we are conducting a prospective randomized trial comparing histopathological findings of surgical excision (Arm 1) to neoadjuvant partial breast irradiation (neoRT) followed by delayed surgical excision (Arm 2) for patients with core needle biopsy proven DCIS. Arm 1 will provide a reference group for upstaging to invasive cancer, molecular markers and pathological-radiological correlations. Arm 2 participants will receive 6 Gy daily x 5 to the intact tumor with a 0.5 cm margin of normal tissue. Surgical excision will be delayed 12-16 weeks to allow for the radioablative effects to occur and radiation-induced inflammation to subside. Specific Aims To determine if neoRT can completely ablate at least 30% of pure DCISTo determine if DCIS subtypes exhibit differential sensitivity to neoRTTo determine the radiation-induced treatment effects; wound complication rates; radiological Eligibility Women 18 years of age or older with DCIS diagnosed on vacuum assisted core needle biopsy who intend to receive breast conserving surgery are eligible, excluding those with a prior history of ipsilateral breast cancer. The imaging abnormality must be mammographic microcalcifications and/or MRI non-mass enhancement measuring Statistics A total of 50 patients will be recruited. Upstaging to invasive cancer is anticipated to be approximately 10% in the reference group. With 25 subjects in each arm, we will have 80% power to detect a 30% or higher improvement in the DCIS complete response rate following neoRT. Accrual Opened to accrual June 1, 2019 Contact wapnir@stanford.edu Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478-488. doi:10.1093/jnci/djr027. McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol. 2015;33(7):709-715. doi:10.1200/JCO.2014.57.9029. Citation Format: Irene Wapnir, Wendy DeMartini, Kimberly Allison, Kimberly Stone, Frederick Dirbas, Carol Marquez, Debra Ikeda, Sunita Pal, Jacqueline Tsai, Rachel Yang, Robert West, Alex McMillan, Melinda Telli, Kathleen Horst. A randomized phase II study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr OT3-09-04.
- Published
- 2020
8. Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss
- Author
-
Julia M. Chandler, Dung Nguyen, Jacqueline Tsai, Irene Wapnir, Arash Momeni, Tammy Ju, and Geoffrey C. Gurtner
- Subjects
Nipple-Sparing Mastectomy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Mammaplasty ,Mastectomy, Subcutaneous ,One stage ,Breast Neoplasms ,Odds ratio ,Surgery ,Oncology ,Ptosis ,Median time ,Nipples ,medicine ,Humans ,Female ,medicine.symptom ,Stage (cooking) ,business ,Mastectomy ,Retrospective Studies - Abstract
BACKGROUND Devascularization of the nipple-areola complex (NAC) before nipple-sparing mastectomy (NSM) enhances blood flow to the skin. This study analyzed the effect of the interval between stages in two-stage (2S) operations and compared the ischemic events with those of one-stage (1S) NSM. METHODS Ischemic complications were defined as partial/reversible (PR) or full-thickness/irreversible (FI) skin necrosis of the NAC or flap. The latter encompassed limited areas of the NAC, resulting in loss of nipple height or areolar circumference without affecting the integrity or appearance of the NAC. Outcomes between the two groups were compared using chi-square and both uni- and multivariate analyses. RESULTS From 2015 to 2019, 109 breasts underwent 2S NSM and 103 breasts underwent 1S NSM. Grade 2 or 3 breast ptosis was more common in the 2S group than in the 1S group (60.5% vs 30.5%; p < 0.01). The median time between devascularization and NSM was 30 days (range, 11-415 days). After devascularization, ischemic events occurred in 25.7% of the breasts. Nipple loss occurred in 7.8% of the 1S group and 0% of the 2S group. Both PR and FI NAC ischemic events were observed in 66.7% of the breasts when NSM took place fewer than 20 days (n = 9) after devascularization versus 15% when NSM took place 20 days or longer afterward (n = 100). Overall, NAC, flap ischemic complications, or both occurred in 35.9% of the 1S group versus 20.2% of the 2S group (p < 0.05). In the multivariate analysis, the odds ratio of ischemic complications in the 2S versus the 1S group was 0.38 (range, 0.19-0.75). CONCLUSIONS Fewer ischemic complications and no nipple loss occurred in 2S NSM. Ischemic events are fewer when the interval between devascularization and NSM is 20 days or longer.
- Published
- 2021
9. Coexisting DCIS and phyllodes breast tumors in Young Chinese women: Case series
- Author
-
Beth Siegel, Jacqueline Tsai, Roger Zhu, Paula S. Ginter, Kap-Jae Sung, J Melissa Hughes, Manmeet Malik, and Luona Sun
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,fungi ,food and beverages ,Phyllodes tumor ,Ductal carcinoma ,medicine.disease ,Benign Phyllodes Tumor ,Article ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Biopsy ,Carcinoma ,Medicine ,Hormonal therapy ,030211 gastroenterology & hepatology ,Surgery ,Radiology ,Stage (cooking) ,business ,Mastectomy - Abstract
Highlights • Breast cystosarcomaphyllodes tumors are rare and can be benign or malignant. • These tumors can harbor carcinomas, although the incidence is extremely rare. • Although challenging, the detection of a carcinoma component in phyllodes tumor is important, as it can dictate the need for lymph node sampling and possible adjuvant therapies such as radiation and systemic management., Introduction Breast cystosarcoma phyllodes tumors are rare and can be benign or malignant. All sub-divisions of phyllodes tumor—benign, borderline and malignant, can harbor carcinomas, although the incidence is extremely rare. Methods: We present two nonconsecutive cases of coexisting ductal carcinoma in situ (DCIS) and phyllodes breast tumors in young patients. Methods & Case Presentation Retrospective review of two patient’s medical record was performed. Case 1 30-year-old female underwent excisional biopsy for 3.48 cm mass found on ultrasound. Pathology revealed malignant phyllodes tumor with positive margin. On re-excision, patient was found to have 1.5 cm area of ductal carcinoma in situ (DCIS) with positive margin. Patient then underwent re-reexicision of DCIS with negative margin. Patient underwent chemotherapy and tamoxifen for three years without evidence of disease. Case 2 30-year-old female presented with 1.3 cm lesion found on ultrasound which core needle biopsy revealed a fibroepithelial tumor. Patient subsequently underwent excision biopsy which found 1.5 cm benign phyllodes tumor and 3.5 mm DCIS within the phyllodes tumor with negative margins. Patient declined additional chemotherapy or hormonal therapy and is currently considering mastectomy. Conclusion Phyllodes tumors are rare and ones with a coexisting carcinoma are even less frequently encountered. The treatment plan can change upon diagnosis of the carcinoma via the pathology. Treatment should be guided by the type and stage of carcinoma detected which may include additional surgical resection and lymph node sampling.
- Published
- 2019
10. ASO Visual Abstract: Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss
- Author
-
Julia M. Chandler, Irene Wapnir, Jacqueline Tsai, Geoffrey C. Gurtner, Tammy Ju, Arash Momeni, and Dung Nguyen
- Subjects
Nipple-Sparing Mastectomy ,medicine.medical_specialty ,Oncology ,Surgical oncology ,business.industry ,medicine ,One stage ,Surgery ,Stage (cooking) ,business - Published
- 2021
11. Surgical excision of BioZorb device eroding through the nipple-areolar complex one year postoperatively: A case report
- Author
-
Tammy Ju and Jacqueline Tsai
- Subjects
medicine.medical_specialty ,Breast surgery ,medicine.medical_treatment ,Planning target volume ,Breast Neoplasms ,Mastectomy, Segmental ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Internal Medicine ,medicine ,Humans ,Nipple areolar complex ,skin and connective tissue diseases ,Mastectomy ,Breast lumpectomy ,Adjuvant radiotherapy ,business.industry ,Surgical debridement ,Ductal carcinoma ,Surgery ,Carcinoma, Intraductal, Noninfiltrating ,Oncology ,030220 oncology & carcinogenesis ,Nipples ,Surgical excision ,Female ,business - Abstract
The recent use of placing a BioZorb device during breast conservation surgery has been shown to improve targeting of adjuvant radiation therapy by significantly reducing target volume to the breast. However, the risks of surgical and/or infectious complications related to a BioZorb placement are largely unknown. In this case report, we describe a patient who underwent BioZorb placement after breast lumpectomy for ductal carcinoma in situ (DCIS), who presented with repeated infections and eventual erosion of the BioZorb through her nipple-areolar complex (NAC), requiring surgical debridement and excision of her NAC and BioZorb 1 year postoperatively.
- Published
- 2020
12. Protecting nipple-areolar complex perfusion by devascularization and surgical delay
- Author
-
Jacqueline Tsai and Irene Wapnir
- Subjects
medicine.medical_specialty ,business.industry ,medicine ,Surgical delay ,General Medicine ,Nipple areolar complex ,business ,Perfusion ,Surgery - Published
- 2021
13. Correction to: Two-Stage Versus One-Stage Nipple-Sparing Mastectomy: Timing of Surgery Prevents Nipple Loss
- Author
-
Julia M. Chandler, Geoffrey C. Gurtner, Tammy Ju, Jacqueline Tsai, Irene Wapnir, Arash Momeni, and Dung Nguyen
- Subjects
Nipple-Sparing Mastectomy ,medicine.medical_specialty ,Oncology ,Surgical oncology ,business.industry ,medicine ,One stage ,Surgery ,Stage (cooking) ,business - Published
- 2021
14. The Impact of Device Innovation on Clinical Outcomes in Expander-based Breast Reconstruction
- Author
-
Alexander Y. Li, Mardi R. Karin, Arash Momeni, Derrick C. Wan, Irene Wapnir, and Jacqueline Tsai
- Subjects
Tissue expander ,medicine.medical_specialty ,Adjuvant radiotherapy ,business.industry ,Rehabilitation ,Successful completion ,030230 surgery ,medicine.disease ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Port (medical) ,Clinical Research ,030220 oncology & carcinogenesis ,Seroma ,Breast Cancer ,medicine ,Postoperative infection ,Original Article ,Patient Safety ,Drain removal ,business ,Breast reconstruction ,Cancer - Abstract
Author(s): Momeni, Arash; Li, Alexander Y; Tsai, Jacqueline; Wan, Derrick; Karin, Mardi R; Wapnir, Irene L | Abstract: Staged expander-based breast reconstruction represents the most common reconstructive modality in the United States. The introduction of a novel tissue expander with an integrated drain (Sientra AlloX2) holds promise to further improve clinical outcomes.MethodsPatients who underwent immediate expander-based pre-pectoral breast reconstruction were identified. Two cohorts were created, that is, patients who underwent placement of a conventional tissue expander [133MX (Allergan)] (Group 1) versus AlloX2 (Sientra) (Group 2). The study endpoint was successful completion of expansion with the objective being to investigate differences in outcome following expander placement.ResultsFifty-eight patients underwent 99 breast reconstructions [Group 1: N = 24 (40 breasts) versus Group 2: N = 34 (59 breast)]. No differences were noted for age (P = 0.586), BMI (P = 0.109), history of radiation (P = 0.377), adjuvant radiotherapy (P = 1.00), and overall complication rate (P = 0.141). A significantly longer time to drain removal was noted in Group 1 (P l 0.001). All patients with postoperative infection in Group 1 required surgical treatment versus successful washout of the peri-prosthetic space via the AlloX2 drain port in 3 of 5 patients in Group 2 (P = 0.196). Furthermore, both cases of seroma in Group 1 required image-guided drainage versus in-office drainage via the AlloX2 drain port in 1 patient in Group 2 (P =0.333).ConclusionThe unique feature of the AlloX2 provides surgeons easy access to the peri-prosthetic space without altering any of the other characteristics of a tissue expander. This resulted in a reduced time to drain removal and facilitated management of postoperative seroma and infection.
- Published
- 2019
15. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer
- Author
-
Melinda L. Telli, Jacqueline Tsai, Irene Wapnir, Danielle M. Bertoni, and Tina Hernandez-Boussard
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Neoplasm, Residual ,medicine.medical_treatment ,Triple Negative Breast Neoplasms ,Kaplan-Meier Estimate ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Humans ,Medicine ,Stage (cooking) ,Lymph node ,Mastectomy ,Neoadjuvant therapy ,Triple-negative breast cancer ,Neoplasm Staging ,business.industry ,Neoadjuvant Therapy ,Log-rank test ,030104 developmental biology ,medicine.anatomical_structure ,Receptors, Estrogen ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Lymph Node Excision ,Female ,Surgery ,Lymph Nodes ,Lymph ,Receptors, Progesterone ,business ,Follow-Up Studies - Abstract
Lymph node ratios (LNR), the proportion of positive lymph nodes over the number excised, both defined as ranges and single ratio values are prognostic of outcome. Little is known of the prognostic value of LNR after neoadjuvant chemotherapy (NAC) according to molecular subtype. From 2003 to 2014, patients who underwent definitive surgery after NAC were identified. LNR was calculated for node-positive patients who received axillary dissection or had at least 6 nodes removed. DFS was calculated using the Kaplan-Meier log rank test for yp N0-3 status, LNR categories (LNRC) ≤0.20 (low), 0.21–0.65 (intermediate), >0.65 (high), and single LNR values. Of 428 NAC recipients, 263 were node negative and 165 (38.6 %) node positive: ypN1 = 97 (58.8 %), ypN2 = 43 (26.1 %), and ypN3 = 25 (15.2 %). Among node-positive cancers, the median number of LN removed was 14 (range, 6–51) and the median LNR was 0.22 (range, 0.03–1.0). Nodal stage was inversely associated with 5-year DFS: 91.5 % (ypN0), 74.5 % (ypN1), 49.8 % (ypN2), and 50.7 % (ypN3) (p
- Published
- 2016
16. Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node
- Author
-
Jafi A. Lipson, Debra M. Ikeda, Nicole Choy, Sunita Pal, Kimberly H. Allison, Wendy MacKerricher, Irene Wapnir, Jacqueline Tsai, Wendy De Martini, and Rupa Patel
- Subjects
Adult ,medicine.medical_specialty ,Axillary lymph nodes ,medicine.medical_treatment ,Sentinel lymph node ,Breast Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Biopsy ,Carcinoma ,medicine ,Humans ,Neoadjuvant therapy ,Aged ,medicine.diagnostic_test ,Tattooing ,business.industry ,Sentinel Lymph Node Biopsy ,Reproducibility of Results ,Sentinel node ,Middle Aged ,medicine.disease ,Prognosis ,Axilla ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Lymph Node Excision ,030211 gastroenterology & hepatology ,Surgery ,Female ,Radiology ,Lymph Nodes ,Sentinel Lymph Node ,business ,Follow-Up Studies - Abstract
Tattooing is an alternative method for marking biopsied axillary lymph nodes (ALNs) before initiation of treatments for newly diagnosed breast cancer. Detection of black ink-stained nodes is performed under direct visualization at surgery and is combined with sentinel node (SLN) mapping procedures. Women with newly diagnosed breast cancer who underwent fine or core-needle biopsy of suspicious ALNs were recruited. The nodal cortex and perinodal soft tissue was injected with 0.1–1.0 ml of Spot™ (GI Supply) black ink under ultrasound guidance. Intraoperatively, black stained nodes were removed along with SLNs, noting concordance between the two. Sixty-six evaluable patients were enrolled (2013–2017). Nineteen received surgery first (Group 1) and 47 neoadjuvant therapy (NAT, Group 2). The average number of nodes tattooed was 1.16 for Group 1 and 1.04 for Group 2. The average interval from tattoo to surgery was 21 days (range 1–62) for Group 1 and 148 days (range 71–257) for Group 2. The tattooed node(s) were visually identified at surgery and corresponded to the sentinel lymph node(s) in 98.5% of cases (18/19 in Group 1 and 47/47 in Group 2). Of the 14 patients in Group 2 whose nodes remained positive following NAT, the tattooed node was the SLN associated with carcinoma. Tattooing is an alternative method for marking biopsied ALNs. Tattooed nodes coincided with SLNs in 98.5% of cases. This technique is advantageous, because it allows for fewer procedures and lower costs compared with other methods.
- Published
- 2018
17. Locoregional Recurrence After Mastectomy
- Author
-
Irene Wapnir, Jacqueline Tsai, and S. Aebi
- Subjects
medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Sentinel node ,medicine.disease ,Confidence interval ,Surgery ,Breast cancer ,medicine ,business ,Adjuvant ,Neoadjuvant therapy ,Mastectomy - Abstract
Mastectomy surgery has been historically judged by its success at preventing local failures after primary invasive breast cancer treatment. Advancements in the use of adjuvant systemic treatments have further reduced the frequency of locoregional recurrences [LRRs], which commonly present as isolated events. Skin-sparing mastectomies, neoadjuvant therapy, and use of sentinel node staging have not increased LRR rates. Chest wall recurrences predominate, and most LRR are clinically detected and operable. The risk of developing a LRR depends of age, tumor size, nodal status, and molecular subtypes as well as prior treatments. Surgical resection and postoperative radiation therapy are therapeutic modalities routinely used to achieve control local disease after LRR. The risk of developing distant metastases and death is elevated. Endocrine and chemotherapy regimens have significantly improved outcomes for this patient population. Specifically, the CALOR trial demonstrated that overall survival was significantly improved with chemotherapy (hazard ratio for death of any cause 0.41; 95% confidence interval 0.0.19–0.89; p = .024), corresponding to a 5-year survival of 88% versus 76%. The recommended drug regimens should be individually tailored based on tumor characteristics and prior treatments.
- Published
- 2018
18. Contributors
- Author
-
Balkees Abderrahman, Stefan Aebi, Prasanna Alluri, Benjamin O. Anderson, Cletus A. Arciero, Raheela Ashfaq, Thomas Aversano, Jennifer Axilbund, Ebrahim Azizi, Rajesh Banderudrappagari, Andrea V. Barrio, Lawrence W. Bassett, Isabelle Bedrosian, Alyssa Berkowitz, Therese B. Bevers, Kirby I. Bland, Cristiano Boneti, Zeynep Bostanci, Ursa Brown-Glaberman, Adam Brufsky, Gwendolyn Bryant-Smith, Oren Cahlon, Benjamin C. Calhoun, Kristine E. Calhoun, Ryan J. Carr, Helena R. Chang, Steven L. Chen, Alice Chung, Maureen A. Chung, Hiram S. Cody, Edward M. Copeland, Ricardo Costa, Jorge I. de la Torre, Amy C. Degnim, Mary L. Disis, William D. Dupont, Melinda S. Epstein, Francisco J. Esteva, David M. Euhus, Suzanne Evans, Oluwadamilola M. Fayanju, Gary M. Freedman, Patrick Bryan Garvey, Abby Geletzke, Mary L. Gemignani, Armando E. Giuliano, Mehra Golshan, William J. Gradishar, Jill Granger, Caprice C. Greenberg, Lars J. Grimm, Stephen R. Grobmyer, Nora Hansen, Ramdane Harouaka, Eleanor E. Harris, Lynn C. Hartmann, Tina J. Hieken, Susan Higgins, Dennis Holmes, Kelly K. Hunt, E. Shelley Hwang, Reshma Jagsi, Sarika Jain, Bharti Jasra, Jacqueline S. Jeruss, Rafael E. Jimenez, Veronica Jones, V. Craig Jordan, Himanshu Joshi, Virginia Kaklamani, Nina J. Karlin, Meghan S. Karuturi, Rena B. Kass, Kenneth Kern, Seema A. Khan, Jennifer R. Klemp, V. Suzanne Klimberg, Soheila Korourian, Henry M. Kuerer, Asangi R. Kumarapeli, Priya Kumthekar, Maryann Kwa, Michael D. Lagios, Jeffrey Landercasper, Kate I. Lathrop, Gordon K. Lee, Stephanie Lee-Felker, A. Marilyn Leitch, D. Scott Lind, Charles L. Loprinzi, Anthony Lucci, Tahra Kaur Luther, Neil Majithia, Issam Makhoul, Melissa Anne Mallory, Anne T. Mancino, Sanjay Maraboyina, Aju Mathew, Damian McCartan, Susan A. McCloskey, Beryl McCormick, Karishma Mehra, Jane E. Mendez, Priya V. Mhatre, Michael D. Mix, Meena S. Moran, Molly Moravek, Leigh Neumayer, Samilia Obeng-Gyasi, Patience Odele, Maureen O'Donnell, Colleen M. O'Kelly Priddy, Ruth M. O'Regan, Sonal Oza, Holly J. Pederson, Angela Pennisi, Margot S. Peters, Sara B. Peters, Lindsay F. Petersen, Melissa Pilewskie, Raquel Prati, Michael F. Press, Erik Ramos, Amy E. Rivere, Arlan L. Rosenbloom, Kathryn J. Ruddy, Kilian E. Salerno, Melinda E. Sanders, Tara Sanft, Cesar A. Santa-Maria, Jennifer Sasaki, Nirav B. Savalia, Chirag Shah, Samman Shahpar, Yu Shyr, Melvin J. Silverstein, Jean F. Simpson, George W. Sledge, Karen Lisa Smith, Stephen M. Smith, George Somlo, Sasha E. Stanton, Vered Stearns, Matthew A. Steliga, Alison T. Stopeck, Toncred M. Styblo, Susie X. Sun, Melinda L. Telli, Amye J. Tevaarwerk, Parijatham S. Thomas, Nicholas D. Tingquist, Jacqueline Tsai, Stephanie A. Valente, Astrid Botty Van den Bruele, Luis O. Vasconez, Doctor Honoris Causa, Frank A. Vicini, Rebecca K. Viscusi, Daniel W. Visscher, Victor G. Vogel, Adrienne G. Waks, Irene L. Wapnir, Thomas Wells, Julia White, Max S. Wicha, Eric P. Winer, Kari B. Wisinski, Debra A. Wong, Teresa K. Woodruff, Eric J. Wright, Melissa Young, and Zachary T. Young
- Published
- 2018
19. Sensitivity and predictive value of ultrasound in pediatric cholecystitis
- Author
-
Jacqueline Tsai, Peter C. Minneci, Jennifer N. Cooper, Jason P. Sulkowski, Katherine J. Deans, and Peter Mattei
- Subjects
Adult ,Male ,medicine.medical_specialty ,Abdominal pain ,Adolescent ,medicine.medical_treatment ,Gallbladder Sludge ,Sensitivity and Specificity ,Predictive Value of Tests ,Interquartile range ,Preoperative Care ,Cholecystitis ,Prevalence ,medicine ,Acute cholecystitis ,Humans ,Child ,Retrospective Studies ,Ultrasonography ,business.industry ,Ultrasound ,Gallbladder ,Hospitals, Pediatric ,medicine.disease ,Predictive value ,Acute Disease ,Chronic Disease ,Female ,Surgery ,Cholecystectomy ,Radiology ,medicine.symptom ,business - Abstract
Background Ultrasonography has a high sensitivity and positive predictive value (PPV) for diagnosing cholecystitis in adults. The objective of this study was to determine the sensitivity and PPV of ultrasonography in the diagnosis of pediatric cholecystitis. Methods We performed a single-institution retrospective review of the records of all patients undergoing cholecystectomy with a preoperative ultrasound during 2005–2010. We calculated sensitivity, specificity, and PPV using pathologic findings as the standard for the diagnosis of cholecystitis. Results In the 223 included patients, the median (interquartile range) age was 14 y (11–16 y); and 64% were female. Preoperative symptoms of abdominal pain were reported in 98% of patients. A diagnosis of cholecystitis was reported in 10% (23 of 223) of ultrasound readings. Pathologic diagnosis of cholecystitis was present in 80% (179 of 223) of cholecystectomy specimens, with 8% (15 of 179) having acute cholecystitis, 83% (148 of 179) chronic cholecystitis, and 9% (16 of 179) both. Sensitivity of ultrasound findings ranged from 6% for Murphy's sign to 66% for cholelithiasis. Positive predictive values ranged from 67% for Murphy's sign to 87% for gallbladder sludge. Presence of any one ultrasound sign had a sensitivity of 82% and PPV of 80%. Conclusions Ultrasound findings in pediatric cholecystitis have lower sensitivities and PPVs than reported in adults. These differences may be explained by the higher prevalence of chronic cholecystitis in children, which suggests that children may have milder episodes of self-limited gallbladder inflammation compared with adults, which may lead to a delay in treatment.
- Published
- 2013
20. Median sternotomy for bilateral pulmonary metastasectomy in children
- Author
-
Peter Mattei and Jacqueline Tsai
- Subjects
Hepatoblastoma ,Male ,Reoperation ,medicine.medical_specialty ,Lung Neoplasms ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Complete resection ,Palpation ,Postoperative Complications ,Postoperative atelectasis ,medicine ,Humans ,Child ,Pneumonectomy ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,Sarcoma ,Retrospective cohort study ,General Medicine ,Length of Stay ,medicine.disease ,Sternotomy ,Surgery ,Treatment Outcome ,Median sternotomy ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,Neoplasm Recurrence, Local ,Metastasectomy ,business ,Hospital stay ,Follow-Up Studies - Abstract
Background Complete resection of metastatic pulmonary nodules in some children may increase survival. We present a series of 16 children who underwent median sternotomy for bilateral pulmonary metastasectomy from January 1, 1999, to December 31, 2010. Methods We reviewed the records of 16 children (3-18 years old, 12 boys, 4 girls) with bilateral pulmonary metastases who underwent median sternotomy with the intent of curative resection. All were treated with alternating single-lung ventilation and careful bilateral manual palpation for nodules. Results The mean number of lesions resected was 11.6 (range, 2-33). Two patients who were found to have lesions that were too numerous to count underwent biopsy only. There were no major complications, and median length of hospital stay was 4 days. One patient had postoperative atelectasis, and another had an air leak; both were discharged on the fifth postoperative day. Seven patients have since died, 2 of whom underwent further resection for recurrent disease, with a median survival of 30 months. Nine patients are currently alive with a median follow-up of 30 months, 2 of whom have recurrent disease. Conclusions Median sternotomy allows excellent exposure of both lungs. In our series, there were no lesions that could not be resected because of inadequate exposure, including several in the left lower lobe posteriorly, and most patients were discharged within 4 days without major complications. In children with metastatic lung disease, median sternotomy is safe and avoids treatment delay and a second operation.
- Published
- 2012
21. The contribution of hiatal hernia to severe gastroesophageal reflux disease in patients with gastroschisis
- Author
-
N. Scott Adzick, Holly L. Hedrick, Alan W. Flake, Pablo Laje, Jacqueline Tsai, Thane A. Blinman, and Joy Collins
- Subjects
Male ,medicine.medical_specialty ,Vomiting ,Fundoplication ,Gestational Age ,Disease ,Infant, Premature, Diseases ,Single Center ,Gastroenterology ,Severity of Illness Index ,Hiatal hernia ,Enteral Nutrition ,Internal medicine ,Prenatal Diagnosis ,medicine ,Humans ,In patient ,Retrospective Studies ,Gastroschisis ,Gastrostomy ,Upper gastrointestinal series ,business.industry ,Incidence (epidemiology) ,Reflux ,Infant, Newborn ,General Medicine ,Infant, Low Birth Weight ,Length of Stay ,medicine.disease ,Combined Modality Therapy ,Surgery ,Early Diagnosis ,Hernia, Hiatal ,Pediatrics, Perinatology and Child Health ,Gastroesophageal Reflux ,Female ,business ,Infant, Premature - Abstract
Background A relationship between gastroschisis-associated gastroesophageal reflux (GER) and hiatal hernia (HH) has not been previously reported. In reviewing our experience with gastroschisis-related GER, we noted a surprising incidence of associated HH in patients requiring antireflux procedures. Methods A single center retrospective chart review focused on GER in all gastroschisis patients repaired between January 1, 2000 and December 31, 2012 was performed. Results Of the 141 patients surviving initial gastroschisis repair and hospitalization, 16 (11.3%) were noted to have an associated HH (12 Type I, 3 Type II, 1 Type III) on upper gastrointestinal series for severe reflux. Ten of the 13 (76.9%) patients who required an antireflux procedure had an associated HH. The time to initiation of feeds was similar in all patients, 19 and 23 days. However, time to full feedings and discharge was delayed until a median of 80 and 96 days, respectively, in HH patients. Conclusions This study describes a high incidence of associated HH in gastroschisis patients. The presence of large associated HH correlated with severe GER, delayed feeding, requirement for antireflux surgery, and a prolonged hospital stay. Patients with gastroschisis and clinically severe GER should undergo early assessment for associated HH.
- Published
- 2013
22. The Use of Eicosanoids to Enhance Donor Cell Engraftment after in Utero Hematopoietic Cell Transplantation (IUHCT)
- Author
-
Aimee G Kim, Matthew M. Boelig, Pulin Li, Michael A. Conner, S Loukogeorgakis, Leonard I. Zon, Alan W. Flake, William H. Peranteau, Haiying Li, and Jacqueline Tsai
- Subjects
business.industry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,Biochemistry ,Immune tolerance ,Transplantation ,Haematopoiesis ,medicine.anatomical_structure ,medicine ,Bone marrow ,Stem cell ,business ,Ex vivo ,Homing (hematopoietic) - Abstract
Introduction In utero hematopoietic cell transplantation (IUHCT) is a nonmyeloablative, nonimmunosuppressive allogeneic transplant approach that has the potential to treat a number of congenital disorders, including hemoglobinopathies and immunodeficiencies. Donor cell engraftment at levels high enough to induce donor specific immune tolerance or to treat a target disease has been elusive and remains a major limitation to the clinical application of IUHCT. One of the most significant barriers to high levels of donor cell engraftment is competition with endogenous fetal hematopoietic stem cells (HSCs) for limited hematopoietic niches following transplant. 16,16-dimethyl-prostaglandin E2 (PGE2) and the epoxyeicosatrienoic acids (EETs) 11,12-EET and 14,15-EET have been shown to enhance donor HSC homing, survival, and cell cycling in postnatal murine and zebrafish models of HSC transplantation. We hypothesized that a single ex vivo treatment of donor cells with these eicosanoids would improve donor cell homing and survival following IUHCT,resulting in higher levels of postnatal donor engraftment. Methods Ten million bone marrow (BM) mononuclear cells from C57Bl/6-GFP mice (H2Kb) were injected intravenously into embryonic day (E14) Balb/c fetuses (H2Kd) via the vitelline vein. Donor cells were treated with vehicle, PGE2, 11,12-EET, or 14,15-EET immediately prior to IUHCT. Early homing to and engraftment of the fetal liver (FL) and spleen (FS) of PGE2 and vehicle treated BM cells at 4, 24 and 72 hours after IUHCT was assessed by flow cytometry. Donor cell survival and apoptosis was also assessed in the FL 96 hours post-IUHCT in these two treatment groups by flow cytometric analysis of intracellular expression of survivin (anti-apoptotic) and anti-caspase 3 (pro-apoptotic). Long-term peripheral blood donor cell engraftment was assessed monthly up to 6 months of age and multilineage engraftment (donor T cells, B cells, granulocytes, and macrophages) was determined at 6 months of age in recipients of all donor cell treatment groups. Statistical analysis was performed using ANOVA with BonferroniÕs multiple comparison test or Kruskal-Wallis with DunnÕs multiple comparison test for normal and non-normal data, respectively. Data reported as mean +/- SEM. Results PGE2 pre-treatment produced a significant increase in FL and FS engraftment at 72 hours post-IUHCT compared to vehicle treated donor cells (FL: 37.5 +/- 3.1% vs 21.6 +/- 1.3%; FS: 52.2 +/- 3.7% vs 39.2 +/- 1.8%; p < 0.05). There was no significant increase in donor cell engraftment in the FL at earlier time points associated with PGE2 treatment. PGE2 treatment was also associated with increased survival of donor cells compared to vehicle treated cells as indicated by increased donor cell expression of survivin (19.8±5.6% vs. 4.6±1.3%; p Conclusions The ex vivo treatment of donor cells with eicosanoids including PGE2, 11,12-EET, and 14,15 EET prior to IUHCT results in enhanced long-term multilineage allogeneic donor cell engraftment. Detailed studies of early homing to fetal hematopoietic organs and survival at 96 hours following IUHCT of PGE2 treated donor cells suggest the mechanism of enhanced engraftment is mainly do to a pro-survival effect of PGE2 and related eicosanoids. This work represents a novel application of these eicosanoids in an allogeneic model of IUHCT and highlights their potential to assist in future clinical applications of IUHCT. Disclosures Zon: FATE Therapeutics: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Other: Founder; Scholar Rock: Employment, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Other: Founder.
- Published
- 2015
23. La Chine et le Luxe
- Author
-
Jacqueline Tsai and Jacqueline Tsai
24. Patch repair for congenital diaphragmatic hernia: is it really a problem?
- Author
-
N. Scott Adzick, Holly L. Hedrick, Alan W. Flake, Jason P. Sulkowski, and Jacqueline Tsai
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Diaphragmatic breathing ,Primary repair ,Recurrence ,Chart review ,Extracorporeal membrane oxygenation ,Medicine ,Humans ,Polytetrafluoroethylene ,Herniorrhaphy ,Retrospective Studies ,High rate ,Hernia, Diaphragmatic ,business.industry ,Patch repair ,Infant, Newborn ,Congenital diaphragmatic hernia ,General Medicine ,Surgical Mesh ,medicine.disease ,Surgery ,Treatment Outcome ,Pediatrics, Perinatology and Child Health ,Synthetic patch repair ,Female ,business ,Hernias, Diaphragmatic, Congenital ,Follow-Up Studies - Abstract
Background Large congenital diaphragmatic hernia (CDH) defects often require the use of synthetic patches for tension-free repair. Although high rates of recurrence and other morbidities have been previously reported, our favorable perception of patch repair prompted this review. Methods A single-center retrospective chart review of CDH cases repaired between January 1, 1999, and October 1, 2010. Patch repairs were performed by multiple surgeons with an effort to construct a tension-free dome-shaped patch. Results One hundred eighty-four children underwent CDH repair of whom 99 (53.8%) required a patch. Seventy-four (74.7%) of the 99 patients who underwent patch repair survived to discharge and were compared with 75 primary repair survivors. Of those undergoing patch repair, 88% were prenatally diagnosed, 55% had liver herniation, and 22 (29.9%) were repaired on extracorporeal membrane oxygenation. Two patients experienced a recurrence after a patch repair and 3 after a primary repair for a rate of 5.4% and 4.0%, respectively ( P = 1.0). Conclusions These results demonstrate that synthetic patch repair for CDH can be performed with a very low rate of recurrence challenging the need for alternative approaches to diaphragmatic replacement. High rates of recurrence reported for patch repair may be technical rather than intrinsic to the patch.
- Published
- 2011
25. A combined strategy of fetal hematopoietic stem cell mobilization and selective enhancement of donor cell homing results in improved engraftment following in utero hematopoietic cell transplantation
- Author
-
Haiying Li, Jason P. Sulkowski, Jacqueline Tsai, Yan Li, Edem Timpo, and Alan W. Flake
- Subjects
Transplantation ,Donor cell ,Fetus ,Hematopoietic cell ,In utero ,business.industry ,Cancer research ,Medicine ,Surgery ,business ,Hematopoietic Stem Cell Mobilization ,Homing (hematopoietic) - Published
- 2012
26. Decreased Sensitivity and Positive Predictive Value of Ultrasound Findings in the Diagnosis of Pediatric Cholecystitis
- Author
-
Peter C. Minneci, Katherine J. Deans, Jason P. Sulkowski, Jacqueline Tsai, and Jennifer N. Cooper
- Subjects
medicine.medical_specialty ,business.industry ,Decreased Sensitivity ,Ultrasound ,Cholecystitis ,Medicine ,Surgery ,Radiology ,business ,medicine.disease ,Predictive value - Published
- 2013
27. Altered Thymocyte Development in Allogeneic in Utero Hematopoietic Cell Transplantation in the Mouse Model
- Author
-
Alan W. Flake, Haiying Li, William H. Peranteau, Yan Li, Jacqueline Tsai, Miho Watanabe, and Jesse D. Vrecenak
- Subjects
medicine.diagnostic_test ,T cell ,Immunology ,Cell Biology ,Hematology ,Biology ,Biochemistry ,Flow cytometry ,Andrology ,Transplantation ,Haematopoiesis ,Thymocyte ,medicine.anatomical_structure ,Immune system ,medicine ,Bone marrow ,CD8 - Abstract
Abstract 4668 Introduction In Utero Hematopoietic Cell Transplantation (IUHCT) is a promising therapeutic strategy for congenital hematopoietic disorders. While mixed allogeneic hematopoietic chimerism with associated donor specific tolerance is routinely achieved by a predominant mechanism of central deletion, the critical events of donor and host thymocyte development have not been analyzed. In this study, we utilized the murine model of allogeneic IUHCT and analyzed donor and host thymocyte development. Methods Bone marrow (BM) cells (10×106) from Foxp3GFP C57/BL6 (B6, H2kb) mice were injected intravenously into Foxp3GFP Balb/c (H2kd) fetuses at embryonic day 14 (E14). At indicated postnatal time points the thymocytes were analyzed by multi-color flow cytometry. Results The results demonstrate that the thymic processing of donor BM-derived thymocytes differs significantly from host thymocytes and from thymocyte development in normal B6 and Balb/c control mice. Though each subpopulation of the host's thymocytes showed comparable levels to the normal untransplanted Balb/c mice, the donor BM-derived thymocytes demonstrated significantly higher proportions of CD4+CD8- and CD4-CD8+ single positive cells, and a dramatically lower proportion of CD4+CD8+ double positive cells compared to their donor-derived counterparts, respectively. These discrepancies increased with each analysis time point up to 12 weeks. Immature single positive cells, including both TCRb-CD4+CD8- and TCRb-CD4-CD8+ cells, were significantly higher in the donor-derived thymocytes than the host, indicating the development of the donor BM-derived thymocytes were impeded at the DN-DP stage in this specific allogeneic IUHCT setting. In addition, we also found higher frequencies and more potent suppressive capacity of regulatory T cells in the donor-derived T cell compartment than in the host T cell compartment. In the reversed allogeneic strain combination, i.e. IUHCT of Foxp3GFP Balb/c BM MNCs into the E14 Foxp3GFP B6 recipients, thymocytes of both origins showed imbalanced intra-thymic development that differed from the normal mouse. Conclusion Our data in the current study suggests that immune reconstitution of the donor bone marrow derived thymocytes differs from that of the host cells and that of normal mice in an allogeneic IUHCT system. The mechanism of the altered thymic development in allogeneic IUHCT, and the potential importance of these observations for clinical IUHCT remains to be determined. Bone marrow (BM) cells (10×106) from Foxp3GFP C57/BL6 (B6, H2kb) mice were injected intravenously into Foxp3GFP Balb/c (H2kd) fetuses at embryonic day 14 (E14). At indicated postnatal time points the thymocytes were analyzed by multicolor flow cytometry (Fig. A), and the expression of TCR¦Â in each individual subpopulation in 4-week old mice was measured (Fig. B). Disclosures: No relevant conflicts of interest to declare.
- Published
- 2012
28. Acute graft vs host disease (GVHD) induced by in utero hematopoietic cell transplantation is reversed by a regulatory response resulting in a potent graft vs hematopoietic effect without clinical GVHD
- Author
-
Edem Timpo, Alan W. Flake, Jason P. Sulkowski, Miho Watanabe, Jesse D. Vrecenak, Yan Li, Jacqueline Tsai, and Haying Li
- Subjects
Transplantation ,Haematopoiesis ,Hematopoietic cell ,In utero ,business.industry ,Immunology ,Medicine ,Surgery ,Host disease ,business - Published
- 2012
29. La Chine et le luxe
- Author
-
Jacqueline Tsai
- Subjects
Sociology - Published
- 2012
30. Acute Gvhd Induced by In Utero Hematopoietic Cell Transplantation Is Reversed by a Regulatory Response Resulting in a Potent Graft Vs. Hematopoietic Effect without Clinical Gvhd
- Author
-
Alan W. Flake, Edem Timpo, Jason P. Sulkowski, Jacqueline Tsai, Miho Watanabe, Jesse D. Vrecenak, and Haying Li
- Subjects
medicine.medical_treatment ,Immunology ,Hematopoietic Tissue ,Spleen ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,Biology ,medicine.disease ,Biochemistry ,Transplantation ,Haematopoiesis ,medicine.anatomical_structure ,Graft-versus-host disease ,medicine ,Bone marrow ,CD8 - Abstract
Abstract 1904 Introduction: In Utero Hematopoietic Cell Transplantation (IUHCT) is a potential treatment for congenital hematologic disorders. The rationale is to utilize normal events during hematopoietic and immunologic development to facilitate hematopoietic engraftment. While the risk of graft versus host disease (GVHD) after IUHCT would be anticipated to be high, based on Medawar's tenets, surprisingly little GVHD has been observed after experimental IUHCT and IUHCT induced GVHD has not been previously characterized. To better understand the potential risk of IUHCT induced GVHD prior to clinical application, we attempted to intentionally induce GVHD pathophysiology in the allogeneic murine model of IUHCT. Methods: Bone marrow (BM) cells (10×106) from C57/BL6 (B6, H2kb, GFP−) mice were co-injected with increasing doses of splenocytes from B6-GFP (H2kb, GFP+) mice intravenously into Balb/c (H2kd) fetuses at embryonic day 14 (E14). Control groups included: 1) 10×106 B6 BM cells alone; 2) same doses of B6-GFP splenocytes alone; and 3) IUHCT of congenic donor cell populations into B6 recipients. Surviving pups were assessed using a clinical GVHD scale and separate cohorts were harvested at pre- and post-natal time-points for analysis by fluorescence stereoscopic microscopy (FSM), flow cytometry for assessment of donor and host cell populations in hematopoietic tissues, and histologic assessment of target tissues for GVHD. Results: Prenatal Analysis - In the allogenic groups that received 10×106 BM cells plus increasing doses of splenocytes (0.1×106 to 10×106 splenocytes/fetus) a consistent distribution of GFP positive cells could be seen by whole body FSM in lymphohematopoietic sites (spleen, lymph nodes, thymus and fetal liver) at E16 that did not differ significantly from congenic controls. By E19 – E20 however, marked proliferation of the cells occurred with clear infiltration of GVHD target organs (skin, lungs, liver, intestine). This expansion was proportionate to the dose of splenocytes and was not seen in congenic or BM only controls. Increased mortality was not observed until doses greater than 5 × 106 splenocytes were given (approx. 5 × 1011 splenocytes/kg est. fetal wt.) with perinatal death likely attributable to respiratory insufficiency. Postnatal Analysis - In the allogeneic groups there was minimal clinical evidence of GVHD up to and inclusive of the 5×106 splenocyte dose. A few pups showed poor growth relative to the normal growth curve and mild fur ruffling, but these resolved by P15, and there was no further clinical evidence of GVHD and no postnatal deaths up to P60. In harvested tissues many GFP+ cells persisted in GVHD target organs, however, no GVHD histopathology was observed at any time. Flow cytometric analysis confirmed a proliferation of donor splenocytes that peaked around P5-P10. Lymphocyte subset analysis revealed an expansion of predominantly CD8+ T-cells. Alkaline phosphatase in the host liver, as a marker of GVHD was increased during the same time course and returned to normal by P15. An increase of host and donor BM derived CD4+ cells was also observed that peaked around P15-17. Further analysis confirmed an increase in both T-regulatory cells and activated CD4+ T-cells compared to normal or BM only controls. The most remarkable observation was a dramatic graft versus hematopoietic (GVH) effect with an increase in donor BM derived chimerism at P60 to > 80% with no clinical GVHD. These findings were seen only in the allogenic group that received both splenocytes and bone marrow cells, not in the other groups. In the group that received only bone marrow cells, the chimerism remained at low levels (Figure 1). Conclusion: Our data demonstrates that the fetus is in fact resistant to GVHD relative to myeloablated postnatal BMT recipients. While there is an aggressive alloimmune activation and expansion of donor T-cells, clinical manifestations are mild and are reversed by what appears to be a T-regulatory cell expansion. In our model, the alloimmune activation phase is accompanied by a potent GVH response providing a competitive advantage for donor cells and resulting in marked enhancement of donor cell engraftment without clinical evidence of GVHD. Further work in this model is directed toward defining regulatory and effector mechanisms involved in controlling GVHD and the GVH effect. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.